InfuSystem Holdings Inc

Análisis de la acción InfuSystem Holdings Inc (INFU)

$13.150

+0.359 (+2.73%)Al cierre

Loading chart…
Máximo
13.590
Apertura
13.140
Precio medio ponderado por volumen
13.21
Volumen
134.96K
Capitalización
145.87M
Mínimo
12.895
Importe
1.78M
EV/EBITDA, TTM
9.35

InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.

ir.infusystem.com

Análisis de IA of InfuSystem Holdings Inc (INFU)

Comprar

InfuSystem Holdings Inc is a good buy right now, with a current price of $13.84 and a forward P/E ratio of 22.73, indicating reasonable valuation relative to future earnings. The company has shown a robust year-to-date change of +64.96% and a solid gross margin of 57.50% in Q2 2026, reflecting strong operational efficiency. The main risk is the high insider selling activity, which has increased by 1158.53% over the last quarter, suggesting potential concerns among hedge funds.

Métricas de valoración

El PER previsto actual de InfuSystem Holdings Inc (INFU) es 22.73, frente a su media de 5 años de 68.23.

PER previsto

Valor razonable
Media 5A P/E
68.23
P/E actual
22.73
Sobrevalorada
139.38
Infravalorada
-2.92

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
8.84
EV/EBITDA actual
9.35
Sobrevalorada
11.12
Infravalorada
6.56

Precio/ventas previsto

Valor razonable
Media 5A P/S
1.43
P/S actual
1.70
Sobrevalorada
1.88
Infravalorada
0.98

Escenarios de precio de Alphio AI para INFU

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%INFU

$7.68

Precio del escenario

B

Base

Base · 50%INFU

$6.54

Precio del escenario

B

Bajista

Bajista · 25%INFU

$6.33

Precio del escenario

Cronología de eventos

2026-08-04 (ET)

07:00:00

Sees 2026 Adjusted EBITDA Margin in Mid to Low 20%'s

07:00:00

Company Reports Q2 Revenue of $36.9M

2026-05-18 (ET)

16:40:00

InfuSystem Approves $20M Stock Repurchase Program

2026-05-07 (ET)

07:30:00

Q1 Revenue at $33.7M, Below Consensus

2026-03-02 (ET)

09:40:00

InfuSystem Trading Resumes

Noticias

Preguntas frecuentes sobre INFU, respondidas por Alphio AI

InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

InfuSystem Holdings Inc is a good buy right now, with a current price of $13.84 and a forward P/E ratio of 22.73, indicating reasonable valuation relative to future earnings. The company has shown a robust year-to-date change of +64.96% and a solid gross margin of 57.50% in Q2 2026, reflecting strong operational efficiency. The main risk is the high insider selling activity, which has increased by 1158.53% over the last quarter, suggesting potential concerns among hedge funds.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar